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Abstract 
Parkinson disease is very common in the world, ranking second to Alzheimer‟s disease in terms of degenerative neurological disorders. 
The disease since 1817 has had so many researchers looking into it, bringing out symptoms, possible treatment options, causes of the 
disorder to mention but a few. There are a number of studies that have looked into the symptoms of the disorder, especially the non-motor 
symptoms of the disorder. This study looks into the motor symptoms associated with the disease. It brought out the causes, which the 
study from the literature review conducted asserted that there is no known cause for it, however, about 60 to 80 percent of persons with 
PD, have a degenerating number of dopamine, as such, this can be postulated to be the cause. The study also affirmed that there is no 
known treatment for the symptoms, doctors and medical practitioners would therefore have to try different forms of treatment till the right 
one for the patient is arrived at. 
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Introduction 
 
Parkinson‟s disease is the second most common degenerative 
neurological disorder after Alzheimer‟s disease [1]. The disease has 
been described by James Parkinson in 1817 as a chronic 
neurodegenerative disease characterized by the loss of dopaminergic 
neurons in the substantia nigra which leads to decreased levels of 
dopamine in the striatum and disrupted motor control. Since its 
description in 1817, there have been a lot of researches being done to 
understand the disorder, with some researches being conducted on its 
prevalence in Sub-Saharan Africa. This proves that the disease is a 
worldwide canker which needs much attention and awareness creation. 
 
It is estimated that the disease affects over 1% of the population over 
the age of 60, which in the UK equates to over 127,000 individuals (or 
500,000 individuals in the USA), while in individuals over the age of 
85 this prevalence reaches 5%, highlighting the impact that advancing 
age has on the risk of developing this condition [2-4]. Williams and 
colleagues [5] reported in their article on Parkinson‟s disease in sub-
Saharan Africa that the disease has a prevalence ranging from 
7/100,000 in Ethiopia to 67/100,000 in Nigeria, with the most recent 
community-based study reporting a mean age at onset of 69.4 years. 
Since no exact test exists for the diagnosis of PD, the exact number of 
people with this disorder cannot be determined, with some being 
misdiagnosed because of the disease‟s similarity to other diseases [6].  
 
Studies have acknowledged that there is a higher chance of PD 
occurring more in men than in women [7], with statistics of it occurring 
in about 50% more men than women [6]. There is no exact reason for 
the differences however some researchers have suggested explanations 
that, the protective effect of estrogen in women, the higher rate of 
minor head trauma, and exposure to occupational toxins in men, and  
 
 
genetic susceptibility genes on the sex chromosomes could account for 
these differences [7]. Gillies and colleagues [8] are however of the 
view that the difference is determined, largely, by biological sex 
differences in the NSDA system which, in turn, arise from hormonal, 
genetic and environmental influences. Over the years, researches have 
concluded that the disorder is not inherited, that is it does not pass 
down through family line. Though some cases of PD occur in families, 
90% of cases are sporadic, meaning they occur without an, as yet, 
identified inherited genetic predisposition [2], simply put, it does not 
happen because one of the family member has it. 
 
Recent researches that have been done on PD attempt to look at the 
causation factors of PD. The purpose of this paper is to review the 
large body of literature on Parkinson‟s disease, looking at what has 
been done so far. It is estimated that the number of people with PD in 
2005 was approximately between 4.1million and 4.6 million and that 
will more than double by 2030 to between 8.7 million and 9.3 million 
[9]. Towards this regard, the paper aims at bringing out a 
comprehensive report on what has been done, with particular attention 
to the symptoms of the disease, examining the early stage symptoms 
and what people should expect.  
  
Pathophysiology of PD 
 
The pathophysiology of PD involves the progressive loss of dopamine-
containing neurons of the pars compacta of the substantia nigra leading 
to denervation of the nigrostriatal tract and significant reduction of 
dopamine at the striatal level [10]. The consequence of this denervation 
process is an imbalance in the striato-pallidal and pallido-thalamic 
output pathways, which is responsible for the major motor deficits 
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[11]. According to Hamani and Lozano [12] the number of 
dopaminergic neurons in the substantia nigra varies from species to 
species, with humans having approximately 220,000 dopaminergic 
neuronsin the substantia nigra of each hemisphere [13]. When more 
than 50 percent of these cells are lost, patients start to develop the signs 
and symptoms of the disease—tremor, rigidity, akinesia and 
bradykinesia (poverty and slowness of movement), as well as postural 
and gait abnormalities [12]. The model proposes that dopamine 
deficiency produces dysfunction in the striatum, leading to decreased 
activity in the direct pathway, from GABAergic striatal neurons to the 
internal segment of the Globus Pallidus (GPi) and substantia nigra 
parsreticulata (SNpr) and an increased drive through the indirect 
pathway, involving particularly the external segment of the Globus 
Pallidus (GPe) and Sub-Thalamic Nucleus (STN). This results in a 
disruption of the activity in basal ganglia output structures (GPi and 
SNpr), which in turn disrupts the activity in brain stem motorareas, 
including the pedunculopontine nucleus and the thalamocortical motor 
system. This disruption is thought to be responsible for the difficulty in 
initiation of movements and the poverty of motion that are 
characteristic of PD. They concluded by bringing out the shortfalls of 
the model which is its inability to adequately explain some of the other 
cardinal features of Parkinson‟s disease, such as tremor or rigidity. 
Further, the model does not take into account that dopamine exerts its 
effects not only in the striatum but also throughout basal ganglianuclei 
and at cortical levels.  
 
Genetic predisposing factors in combination with environmental 
factors are thought to be responsible for the cellular changes leading to 
progressive neuronal degeneration in which mitochondrial dysfunction, 
oxidative mechanisms and failure of the protein degradation machinery 
at the cellular level are probably involved [14]. The presence of Lewy 
bodies (cytoplasmic proteinaceous inclusions) in surviving 
dopaminergic neurons is the pathological hallmark of PD [10] (Figures 
1 and 2). 
 
Figure 1: Parkinson‟s Disease 
 
Figure 2: Dopamine levels in a normal and a Parkinson‟s affected 
neuron 
 
Motor Symptoms 
 
Researches that have been done to look at the symptoms associated 
with Parkinson‟s Disease (PD) have shown that it is a degenerative 
neurological disorder, associated with primary and secondary motor 
symptoms [15]. Although it has been assumed that the various motor 
symptoms in PD are caused solely by striatal dopamine depletion 
[16,17], many studies have shown that additional neural structures and 
neurochemical systems are also responsible for the occurrence of motor 
symptoms in PD; these include prefrontal cortical areas and the 
cerebellum, as well as serotonergic, glutamatergic, and cholinergic 
systems [18,19]. For the purpose of the study, motor symptoms of PD 
that will be considered will be akinesia, bradykinesia, tremor and 
rigidity. 
 
Akinesia  
Akinesia is a term for the loss of ability to move your muscles 
voluntarily. In describing this symptom of PD, Kinnier Wilson had this 
to say “it seems as if the patient does not care to continue the task or 
put an adequate amount of effort into a particular movement” [20]. 
Even though a major symptom of PD, akinesia can also appear as a 
symptom for other conditions too. According to a study in the Journal 
of Neurology, Neurosurgery & Psychiatry, 47 percent of more than 
6,600 people with Parkinson's disease who responded to a 
questionnaire reported akinesia or freezing as a symptom.  
 
Akinesia is characterized by abnormal stiffness due to increased tone 
of both the agonist and antagonist muscles (lead pipe) or cogwheel 
rigidity due to superimposed or underlying tumor [21]. Akinesia can 
also be referred to as freezing. Some of the symptoms associated with 
akinesia include difficulty when a person starts out to walk somewhere, 
muscle rigidity, usually beginning in the neck and legs, muscles in the 
face can also become rigid, similar to a mask and there is also sudden 
inability to move the feet properly, especially when turning or 
approaching a destination [22]. Usually Parkinson associated akinesia 
is brought about as a result of a reduction in dopamine in the brain, 
causing a difficulty in the ability to move body parts [22]. 
  
Treatments for Parkinson's disease-related akinesia can be more 
complicated as no one treatment can be used or is known to cure this 
symptom. Doctors will often prescribe medications that increase the 
amount of the neurotransmitter dopamine in the body or the activity it 
causes. Getting regular exercise can help you reduce the pain and 
discomfort that can happen with akinesia and other motor function 
conditions that may result from PD. It will be advised for a patient with 
this symptom to talk to a doctor or a physical therapist about 
developing an exercise plan that‟s comfortable and safe depending on 
the symptoms and the progression of akinesia. Exercise has been 
shown to delay functional decline in PD. 
 
Bradykinesia  
Bradykinesia has its origination from Greek words „slow‟ and 
„movement‟. The term which describes slowness in carrying out, rather 
than initiating, movements was first used by Dr James Parkinson in 
1817. Bradykinesia is one of the early signs of a movement disorder 
such as Parkinson‟s or Parkinsonism. A doctor or neurologist who 
observes bradykinesia may well suspect that the person has 
Parkinson‟s. The exact cause of the disorder is unknown [23], however, 
there are evidence of it being caused by reduced levels of dopamine in 
the brain and is often first noticed by family and friends. Movement is 
particularly impaired when novel movements are attempted [24], or 
when several movements are combined [25,26]. Whereas in akinesia 
there is the inability to move body parts or a difficulty in movement, in 
bradykinesia there is slowness in movement.  
 
Theoretically, bradykinesia can be categorized into the verbal-
conceptual models and the mathematical and computational models 
[23]. The verbal-conceptual models describe the brain areas, pathways 
and interactions thought to lead to parkinsonian bradykinesia whereas 
the mathematical and computational models describe the interactions 
between the various brain areas involved in movement control and 
execution that are relevant in parkinsonian bradykinesia [23].  
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Bradykinesia cannot be cured; however, the symptoms can be managed 
somewhat with medications. The most helpful medications for 
bradykinesia are those that increase dopamine levels. Doctors can try 
various medicines until the right one for the patient is found. The 
challenge here will be finding the right medication for the patient due 
to the medications becoming less effective over time. There are 
therefore other treatment plans that doctors can plan for their patients. 
There is the surgical procedure known as deep brain stimulation that 
may be used for certain people living with Parkinson‟s. This treatment 
involves surgically placing electrodes into specific locations in your 
brain. Once the electrodes are in place, the patient will have electrical 
impulses sent to stimulate the brain at the electrode sites. This 
treatment is normally reserved for those with severe Parkinson who do 
not respond well to traditional medications. The patient can also adopt 
lifestyle remedies for symptom management. Usually, whether you are 
taking medications or not, there are lifestyle changes and steps a 
patient with bradykinesia associated with Parkinson can add at home as 
part of their treatment plan. However, they should be sure to talk to 
their doctor or medical practitioner before adding anything to the 
treatment plan. Some of these lifestyle or home treatments may include 
eating a healthy diet usually high in fiber, doing physical therapy with 
exercises that increase strength, balance, and flexibility like walking 
and swimming, and taking the steps needed to help avoid falling [27]. 
 
Tremor  
A tremor is an involuntary quivering movement or shake. It is 
characterized clinically by involuntary, rhythmic and alternating 
movements of one or more body parts [28]. A consensus statement of 
the Movement Disorder Society has classified three tremor syndromes 
associated with Parkinson's disease [29] to include resting, postural, 
and kinetic. Tremor is very common in Parkinson‟s, affects about 80% 
of people with Parkinson‟s [30]. The tremor that occurs in Parkinson‟s 
disease is different than almost all other tremors because it is a “resting 
tremor,” present primarily at rest [30]. It goes away with movement, 
but often returns when the limb (usually a hand or the fingers) is held 
in one position, as in holding a spoon or fork to the mouth, which is 
why those with Parkinson‟s are known to spill things. Parkinson‟s 
disease tremor may affect almost any part of the body, but most 
commonly involves the fingers, followed next most commonly by the 
hands, jaw, and feet in that order [30]. 
 
The resting tremor is a tremor that occurs during voluntary movements 
[31]. Resting tremor occurs when the muscle is relaxed, such as when 
the hands are resting on the lap. With this, a person‟s hands, arms, or 
legs may shake even when they are at rest [32]. Often, the tremor only 
affects the hand or fingers. This type of tremor is also called a “pill-
rolling” tremor because the circular finger and hand movements 
resemble rolling of small objects or pills in the hand [33]. Parkinsonian 
tremor is caused by damage to structures within the brain that control 
movement [32]. This resting tremor, which can occur as an isolated 
symptom or be seen in other disorders, is often a precursor to 
Parkinson‟s disease. The symptoms of this tremor can be evidently 
increased by stress or emotions. Approximately 70% of PD patients 
experienced tremor during the course of the disease [34]. There is no 
cure for tremor; however, the medication for the treatment of 
Parkinson‟s disease can be used to control this symptom.  
 
Rigidity  
Rigidity has been defined by Xia and Rymer [35] as an increased 
resistance of a joint to passive movement. The resistance is essentially 
constant throughout the range of movement [35]. Rigidity is associated 
with feeling of stiffness experienced by the patient, and clinicians may 
assess rigidity by examining the resistance of a muscle against passive 
stretching [36]. One of the major manifestations of Parkinson's disease 
is rigidity. The only symptom unequivocally produced by rigidity is a 
feeling of stiffness [36]. This term refers to the phenomenon of 
increased resistance when stretching a muscle passively. Although 
some features of rigidity have been characterized, the detailed 
physiology is still unknown [37], it is believed that it is associated with 
the reduction in dopamine, a neurotransmitter (chemical messenger) 
that relays the message to particular areas of the brain to produce 
smooth, purposeful movement [38]. It has been estimated that about 90 
to 99 percent of people with Parkinson‟s experience rigidity. Rigidity 
is often associated with slowness of movement (bradykinesia). It is 
often preceded by aching, stiffness or a feeling of weakness in the 
muscles [39]. Everyone‟s experience is different but often rigidity 
starts in one arm, spreads to the leg on that side and then to the trunk 
and other side of the body. Rigidity will progress faster in some people 
than in others [39].  
 
Though there is no definite cure for rigidity, a number of treatments 
could be applied till the best cure is achieved. Treatment is tailored to 
the individual patient and may include medications, surgery (deep 
brain stimulation), and complementary or alternative medicine [38]. A 
physiotherapist can advise on exercises to maintain or improve both 
mobility and the range of movement in muscles and joints. He or she 
can also suggest strategies to perform daily activities in a more 
effective way, for example how to roll in bed or get up from a chair. 
An occupational therapist or physiotherapist will be consulted to advice 
on devices and aids to help you in your everyday life [39]. Choice of 
therapy should be customized to the individual patient with an 
understanding of the risks and benefits of each class of medication 
[40]. 
 
Conclusion 
 
The motor symptoms of PD are the very first symptoms you will notice 
in a patient with the disease. Usually, it is the motor symptoms that 
doctors and other medical practitioners use as a basis for diagnosing 
the disease since there is no definite test. This article looked at 
literature on the motor symptoms of the disease, how you can identify 
them and the steps you can take towards the treatment. From the 
researches reviewed it was identified that there is usually no major 
known cause for these symptoms, but usually when the motor 
symptoms of PD appear, 60 to 80 percent of the neurons that generate 
dopamine have been destroyed [6]. It can therefore be concluded that 
these symptoms are brought about from the reduction of dopamine. 
Even in the treatment of these symptoms, medicines that increase the 
level of dopamine in the system are recommended. It was also realized 
that there was no definite cure for these symptoms just as the disease 
itself; however, there are treatments that can help reduce the problems 
associated with these symptoms. There has not been much work done 
on the reason for the delay in finding a cure for the disease, however, 
Dr. Soania Mathur [41] in an article has highlighted some reasons for 
this, which includes the brain being too complicated coupled with a 
complicated disease making it difficult to find a cure. It can be 
concluded that drugs that are being prescribed for Parkinson‟s can be 
used to treat these symptoms. There are also other forms of treatments 
like medical surgery, exercises and change of lifestyles that can help 
with these symptoms. Due to the unknown cure for the symptoms, 
doctors would have to try on different treatment plans to arrive at the 
best solution for the symptoms. 
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